IL76554A - Prolonged release of biologically active somatotropins - Google Patents

Prolonged release of biologically active somatotropins

Info

Publication number
IL76554A
IL76554A IL76554A IL7655485A IL76554A IL 76554 A IL76554 A IL 76554A IL 76554 A IL76554 A IL 76554A IL 7655485 A IL7655485 A IL 7655485A IL 76554 A IL76554 A IL 76554A
Authority
IL
Israel
Prior art keywords
compsn
biologically active
prolonged release
stearate
zinc
Prior art date
Application number
IL76554A
Other languages
English (en)
Other versions
IL76554A0 (en
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24638364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL76554(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of IL76554A0 publication Critical patent/IL76554A0/xx
Publication of IL76554A publication Critical patent/IL76554A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Feed For Specific Animals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Holo Graphy (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Fodder In General (AREA)
IL76554A 1984-10-04 1985-10-03 Prolonged release of biologically active somatotropins IL76554A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65771384A 1984-10-04 1984-10-04

Publications (2)

Publication Number Publication Date
IL76554A0 IL76554A0 (en) 1986-02-28
IL76554A true IL76554A (en) 1990-04-29

Family

ID=24638364

Family Applications (1)

Application Number Title Priority Date Filing Date
IL76554A IL76554A (en) 1984-10-04 1985-10-03 Prolonged release of biologically active somatotropins

Country Status (28)

Country Link
US (2) US5013713A (fr)
EP (1) EP0177478B2 (fr)
JP (1) JPH0745409B2 (fr)
KR (1) KR890002631B1 (fr)
CN (2) CN1007124B (fr)
AT (1) ATE132372T1 (fr)
AU (1) AU573904B2 (fr)
BG (1) BG47039A3 (fr)
CA (1) CA1309018C (fr)
CS (1) CS274717B2 (fr)
CZ (1) CZ284472B6 (fr)
DD (1) DD244914A5 (fr)
DE (2) DE3582548D1 (fr)
DK (1) DK449585A (fr)
ES (1) ES8702440A1 (fr)
GE (1) GEP19960332B (fr)
GR (1) GR852398B (fr)
HU (1) HU196714B (fr)
IE (1) IE65392B1 (fr)
IL (1) IL76554A (fr)
NO (1) NO173975C (fr)
NZ (1) NZ213701A (fr)
PL (2) PL261273A1 (fr)
PT (2) PT81248B (fr)
SU (1) SU1595330A3 (fr)
UA (1) UA8352A1 (fr)
YU (1) YU45281B (fr)
ZA (1) ZA857642B (fr)

Families Citing this family (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5037806A (en) * 1985-02-22 1991-08-06 Monsanto Company Biologically active method using somatotropins
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
IL79765A (en) * 1985-08-23 1992-02-16 Lilly Co Eli Injectable sustained release formulations of bovine somatotropin
US4857506A (en) * 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
EP0279616A3 (fr) * 1987-02-17 1990-03-07 International Minerals And Chemical Corporation Augmentation de la croissance du porc
US4863736A (en) 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
GB8725427D0 (en) * 1987-10-30 1987-12-02 Lilly Industries Ltd Somatotropin formulations
US5021554A (en) * 1989-02-24 1991-06-04 Eli Lilly And Company Process for protein particle size reduction using a fluid-energy mill
DK168790D0 (fr) * 1990-07-13 1990-07-13 Novo Nordisk As
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
US6894023B1 (en) 1990-07-13 2005-05-17 Novo Nordisk A/S Growth hormone crystals and a process for production of these GH-crystals
YU87892A (sh) * 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
DK0661989T3 (da) * 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
ZA949350B (en) 1994-01-25 1996-05-24 Upjohn Co Aqueous prolonged release formulation
PT779806E (pt) * 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
DK0873134T3 (da) * 1996-01-11 2003-08-11 Upjohn Co Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
US5767080A (en) * 1996-05-01 1998-06-16 Cargill, Incorporated Enhanced milk production in dairy cattle
KR20090007504A (ko) 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
KR20030023878A (ko) * 2000-06-26 2003-03-20 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 계면활성제 함유비수성 제제들
US6664234B1 (en) * 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
JP2006199589A (ja) * 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
JP5242375B2 (ja) 2005-04-01 2013-07-24 ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア ホスホノ−ペント−２−エン−１−イルヌクレオシド及び類似体
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP1981525B1 (fr) 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Liberation etendue de neureguline destinee a ameliorer la fonction cardiaque
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
MX2008011842A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica.
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
PT2066662E (pt) 2006-09-21 2013-02-13 Kyorin Seiyaku Kk Inibidores de serina-hidrolase
CA2666149A1 (fr) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Indoles substitues
WO2008057604A2 (fr) * 2006-11-08 2008-05-15 The Regents Of The University Of California Agents thérapeutiques contenant de petites molécules, synthèses d'analogues et de dérivés et leurs procédés d'utilisation
WO2008106167A1 (fr) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
CA2696053A1 (fr) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Procedes de traitement de maladies hepatiques
HUE031070T2 (en) 2007-03-15 2017-06-28 Auspex Pharmaceuticals Inc Deuterated d9-venlafaxine
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
CN101801188A (zh) * 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
CA2699152C (fr) 2007-09-12 2015-11-24 Activx Biosciences, Inc. Aminoquinolones spirocycliques utilisees en tant qu'inhibiteurs de gsk-3
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2547406T3 (es) 2008-03-17 2015-10-06 Ambit Biosciences Corporation Derivados de moduladores como moduladores de quinasas RAF y metodo de uso de los mismos
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
NZ589469A (en) * 2008-05-20 2012-08-31 Cerenis Therapeutics Holding S A Niacin and NSAID combination for reducing niacin-induced flushing
WO2010014134A1 (fr) 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Composés et compositions pharmaceutiques pour le traitement d'infections virales
EP2324034A4 (fr) * 2008-08-22 2012-05-16 Orchid Chemicals & Pharm Ltd Sel de sodium cristallin de l'antibiotique céphalosporine
EP2376524B1 (fr) 2008-12-31 2017-03-15 Cypralis Limited Dérivés de cyclosporine a
WO2010088450A2 (fr) 2009-01-30 2010-08-05 Celladon Corporation Procédés de traitement de maladies associées à la modulation de serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
DK2401267T3 (en) 2009-02-27 2014-03-10 Ambit Biosciences Corp JAK-kinase modulating quinazoline derivatives AND THEIR APPLICATION IN PROCESSES
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
EP2406266B1 (fr) * 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones comme inhibiteurs de la gsk-3
WO2010105016A1 (fr) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combinaison d'une indazolylaminopyrrolotriazine et d'un taxane pour un traitement du cancer
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (fr) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation en thérapie anticancéreuse
AR076363A1 (es) 2009-04-22 2011-06-08 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida
SG10201505313RA (en) 2009-04-22 2015-08-28 Axikin Pharmaceuticals Inc 2,5-Disubstituted Arylsulfonamide CCR3 Antagonists
CA2758985A1 (fr) 2009-04-22 2010-10-28 Axikin Pharmaceuticals, Inc. Antagonistes ccr3 d'arylsulfonamides 2,5-disubstitues
WO2011003870A2 (fr) 2009-07-06 2011-01-13 Creabilis S.A. Corticostéroïdes mini-pegylés, compositions les comprenant et procédés pour les préparer et les utiliser
AR080945A1 (es) 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
EP3213756A1 (fr) 2009-07-08 2017-09-06 Hope Medical Enterprise, Inc. D.b.a. Hope Pharmaceuticals Compositions pharmaceutiques contenant du thiosulfate de sodium
WO2011009961A1 (fr) 2009-07-24 2011-01-27 Virologik Gmbh Association d'inhibiteurs du protéasome et de médicaments anti-hépatite dans le traitement de l'hépatite
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
WO2011022473A1 (fr) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Composés biaryles et procédés d’utilisation de ceux-ci
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (fr) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Imidazo[2,1-b][1,3]benzothiazoles enrichis en isotopes ou fluores
WO2011064769A1 (fr) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procédés et compositions pharmaceutiques pour le traitement des bouffées de chaleur
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
JP2013515080A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
WO2011079313A1 (fr) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Analogues d'ergoline
KR20120125610A (ko) 2009-12-30 2012-11-16 싸이넥시스, 인크. 시클로스포린 유사체
WO2011089167A1 (fr) 2010-01-19 2011-07-28 Virologik Gmbh Inhibiteur du protéasome destiné à traiter le vih
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
EA027622B1 (ru) 2010-02-05 2017-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Твердофазные формы макроциклических ингибиторов киназы
SI3202461T1 (sl) 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
US8999995B2 (en) 2010-03-02 2015-04-07 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (fr) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Sels d'indazolylpyrrolotriazine
WO2011116161A2 (fr) 2010-03-17 2011-09-22 Axikin Pharmaceuticals Inc. Antagonistes du ccr3 de type arylsulfonamide
US9296722B2 (en) 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (fr) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Composés azolylamide et leurs procédés d'utilisation
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
AU2011261501B2 (en) 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス, エルエルシーNovomedix, Llc フラニル化合物およびその使用
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2611448A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Dérivés de 7-cyclylquinazoline et leurs méthodes d'utilisation
AU2011296074B2 (en) 2010-09-01 2015-06-18 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
CA2810024A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composes de quinazoline et leurs methodes d'utilisation
WO2012030924A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composés d'azolopyridine et d'azolopyrimidine et méthodes d'utilisation associées
EP2611793A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Dérivés de 2-cycloquinazoline et leurs méthodes d'utilisation
EP2611794A1 (fr) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Dérivés de 4-azolylaminoquinazoline et leurs méthodes d'utilisation
US8633209B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030918A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composés de modulation du récepteur a3 de l'adénosine et leurs méthodes d'utilisation
WO2012030944A2 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composés quinoléine et isoquinoléine et leurs procédés d'utilisation
WO2012030894A1 (fr) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composés thiénopyridines et thiénopyrimidines et leurs procédés d'utilisation
WO2012044641A1 (fr) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinylbenzimidazolsulfonamides et leur utilisation en thérapie anticancéreuse
JP2013543512A (ja) 2010-10-11 2013-12-05 アクシキン ファーマシューティカルズ インコーポレーテッド アリールスルホンアミドｃｃｒ３アンタゴニストの塩
EP2637669A4 (fr) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Composés hétérocycliques et utilisations de ceux-ci
CA2819859A1 (fr) 2010-12-06 2012-06-14 Follica, Inc. Procedes destines a traiter la calvitie et a favoriser la croissance des cheveux
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
EP2683384B1 (fr) 2011-03-11 2015-12-09 Celgene Corporation Methodes de traitement du cancer au moyen de 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
EP2691388A1 (fr) 2011-03-28 2014-02-05 MEI Pharma, Inc. (arylamino et hétérocyclylamino à cycle condensé)pyrimidinyl- et 1,3,5-triazinylbenzimidazoles, compositions pharmaceutiques de ceux-ci et leur utilisation dans le traitement de maladies prolifératives
WO2012135175A1 (fr) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (cycloalkylamino ou hétérocyclylamino alpha-substitué) pyrimidinyl et 1,3,5-triazinyl benzimidazoles, compositions pharmaceutiques les contenant et leur utilisation dans le traitement des maladies prolifératives
EP2691384B1 (fr) 2011-03-28 2016-10-26 MEI Pharma, Inc. (aralkylamino- et heteroaralkylamino)-pyrimidinyl- et 1,3,5-triazinyl-benzimidazoles substitues sur la position alpha, compositions pharmaceutiques les contenant et ces composes destines a etre utilises dans le traitement des maladies proliferatives
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
WO2013032591A1 (fr) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Composés hétérocycliques et leurs utilisations
EP2755983B1 (fr) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales
CN103906759A (zh) 2011-09-12 2014-07-02 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
ES2586527T3 (es) 2011-10-14 2016-10-17 Ambit Biosciences Corporation Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
WO2013095707A1 (fr) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Nouveaux dérivés d'iso-ergoline
EP2793583A4 (fr) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc Nouveaux composés neuromodulateurs
WO2013130600A1 (fr) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Formes solides comprenant de la pyrazolylaminoquinazoline optiquement active, compositions à base de celles-ci et leurs utilisations
TW201341367A (zh) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc ３，５－二胺基吡唑激酶抑制劑
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EA031301B1 (ru) 2012-05-22 2018-12-28 Иденикс Фармасьютикалз Ллс D-аминокислотные химические соединения для лечения заболеваний печени
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
SG11201500983RA (en) 2012-08-09 2015-04-29 Celgene Corp Treatment of immune-related and inflammatory diseases
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN104781240A (zh) 2012-09-07 2015-07-15 埃克希金医药品有限公司 同位素富集的芳基磺酰胺ccr3拮抗剂
WO2014055647A1 (fr) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl et sulfonyl benzimidazolyl) pyrimidines et triazines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter les maladies prolifératives
MX353422B (es) 2012-10-08 2018-01-12 Idenix Pharmaceuticals Llc Análogos de 2'-cloronucleósido para infección por vhc.
WO2014063019A1 (fr) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Composés dinucléotides contre une infection par le vhc
EP2909222B1 (fr) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC Nucléosides 2', 4'-pontés pour l'infection par le vhc
MX2020009849A (es) 2012-11-01 2021-09-13 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
CA2890177A1 (fr) 2012-11-08 2014-05-15 Summa Health System Vitamine c, vitamine k, un polyphenol et leurs combinaisons pour la cicatrisation des plaies
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014078436A1 (fr) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. Ester de d-alanine d'analogue de sp-nucléoside
US9156781B2 (en) 2012-11-30 2015-10-13 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
EP2935304A1 (fr) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
SG11201504931SA (en) 2012-12-21 2015-07-30 Map Pharmaceuticals Inc Novel methysergide derivatives
EP2943188A1 (fr) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamines c et k pour le traitement de maladies polykystiques
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970194A1 (fr) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US20140377258A1 (en) 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
WO2014197578A1 (fr) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
WO2015017713A1 (fr) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. Pronucléotides phosphoramidates avec acides aminés d de composés halogéno pyrimidines pour le traitement des hépatopathies
EP3039021A1 (fr) 2013-08-30 2016-07-06 Ambit Biosciences Corporation Composés de biaryle acétamide et procédés d'utilisation de ceux-ci
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (fr) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2015051336A1 (fr) 2013-10-03 2015-04-09 David Wise Compositions et procédés pour le traitement de la douleur pelvienne et d'autres états douloureux
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (fr) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
WO2015081133A2 (fr) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucléotides pour le traitement du cancer du foie
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
CN103746201B (zh) * 2013-12-18 2016-04-20 宁波意欧迅网络通信有限公司 高频数据插头和电子配线线缆
WO2015095419A1 (fr) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. Nucléosides 4'-or pour le traitement du vhc
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
AU2015231215B2 (en) 2014-03-20 2019-07-18 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
DK3119762T3 (da) 2014-03-20 2021-08-30 Capella Therapeutics Inc Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
WO2015157559A2 (fr) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. Saxitoxines 10',11'-modifiées pour le traitement de la douleur
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2015168079A1 (fr) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
CA2948540A1 (fr) 2014-05-12 2015-11-19 Conatus Pharmaceuticals Inc. Traitement des complications de maladies hepatiques chroniques avec des inhibiteurs de caspase
CA2947939A1 (fr) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Derives de nucleosides pour le traitement du cancer
WO2015195474A1 (fr) 2014-06-18 2015-12-23 Biotheryx, Inc. Dérivés d'hydroxypyridone, compositions pharmaceutiques contenant lesdits dérivés, et leur utilisation thérapeutique pour traiter des maladies inflammatoires, neurodégénératives ou d'origine immunologique
US10227342B2 (en) 2014-06-19 2019-03-12 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
AU2015314830B2 (en) 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
AU2015335950B2 (en) 2014-10-21 2018-01-25 Takeda Pharmaceutical Company Limited Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl}pyrimidine-2,4-diamine
WO2016065264A1 (fr) 2014-10-24 2016-04-28 Biogen Ma Inc. Dérivés de diterpénoïdes et leurs procédés d'utilisation
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
CN107428745A (zh) 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
EP3303361A1 (fr) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucléotides pour le traitement du cancer
MY189806A (en) 2015-06-23 2022-03-08 Neurocrine Biosciences Inc Vmat2 inhibitors for treating neurological diseases or disorders
EP3995589A1 (fr) 2015-08-17 2022-05-11 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux à l'aide d'inhibiteurs de farnésyltransférases
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
CN108473489B (zh) 2015-10-30 2022-09-02 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
WO2017079566A1 (fr) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP6869988B2 (ja) 2015-12-23 2021-05-12 ニューロクライン バイオサイエンシーズ，インコーポレイテッド （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
MX2018008421A (es) 2016-01-08 2019-12-09 Celgene Corp Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
WO2017120422A1 (fr) 2016-01-08 2017-07-13 Celgene Corporation Composés antiprolifératifs, leurs compositions pharmaceutiques et leurs utilisations
CA3010794A1 (fr) 2016-01-08 2017-07-13 Celgene Corporation Formes solides de 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)methyl)-2,2-difluoroacetamide, compositions pharmaceutiques et utilisations de celles-c
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
CA3020681A1 (fr) 2016-04-11 2017-10-19 Clexio Biosciences Ltd. Derives de ketamine deuteres
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
WO2017184968A1 (fr) 2016-04-22 2017-10-26 Kura Oncology, Inc. Méthodes de sélection de patients atteints de cancer pour le traitement avec des inhibiteurs de farnésyltransférase
WO2017190086A1 (fr) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Composés de pyrazole di-substitués pour le traitement de maladies
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3036195A1 (fr) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Composes de pyrazole di-substitues pour le traitement de maladies
EP3515414B1 (fr) 2016-09-19 2022-11-30 MEI Pharma, Inc. Polythérapie
CA3042747A1 (fr) 2016-11-03 2018-05-11 Kura Oncology, Inc. Methodes de traitement de patients cancereux par inhibiteurs de farnesyltransferase
WO2018089692A1 (fr) 2016-11-09 2018-05-17 Phloronol, Inc. Dérivés d'eckol, procédés de synthèse et utilisations associées
US10988442B2 (en) 2016-11-09 2021-04-27 Novomedix, Llc Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
EP3548007A4 (fr) 2016-12-01 2020-08-12 Ignyta, Inc. Méthodes de traitement du cancer
TW201827051A (zh) 2016-12-02 2018-08-01 美商神經性分泌生物科學公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018140093A1 (fr) 2017-01-27 2018-08-02 Obrien Christopher F Procédés d'administration de certains inhibiteurs de vmat2
CN109475550A (zh) 2017-02-21 2019-03-15 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症的方法
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (fr) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Posologie pour la valbénazine
EP3601326A4 (fr) 2017-03-20 2020-12-16 The Broad Institute, Inc. Composés et méthodes de régulation de sécrétion d'insuline
CN110799192A (zh) 2017-03-27 2020-02-14 加利福尼亚大学董事会 治疗癌症的组合物和方法
JP2020515611A (ja) 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
KR20200012833A (ko) 2017-03-29 2020-02-05 사이트원 테라퓨틱스, 인코포레이티드 통증 치료용 11,13-개질된 색시톡신
WO2018200605A1 (fr) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la dyskinésie induite par la lévodopa
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN111093658B (zh) 2017-05-19 2022-10-14 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
EP3624796A1 (fr) 2017-05-19 2020-03-25 NFlection Therapeutics, Inc. Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
WO2018223065A1 (fr) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Dérivés d'ergoline destinés à être utilisés en médecine
WO2019032489A1 (fr) 2017-08-07 2019-02-14 Kura Oncology, Inc. Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW201919622A (zh) 2017-09-21 2019-06-01 美商紐羅克里生物科學有限公司 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組
EP3691658A4 (fr) 2017-10-04 2021-06-23 The Regents of The University of California Oligosaccharides immunomodulateurs
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
WO2019113269A1 (fr) 2017-12-08 2019-06-13 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (fr) 2018-01-10 2019-07-18 Cura Therapeutics Llc Compositions pharmaceutiques comprenant des acides dicarboxyliques et leurs applications thérapeutiques
JOP20200298A1 (ar) 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
WO2020006341A1 (fr) 2018-06-29 2020-01-02 Conatus Pharmaceuticals, Inc. Dérivés d'acide (s)-3-(2-(4-(benzyl)-3-oxopipérazin-1-yl)acétamido)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque et composés apparentés utilisés en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
EP3860714B1 (fr) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. Saxitoxines 11,13-modifiées destinées au traitement de la douleur
EP3873469A2 (fr) 2018-11-01 2021-09-08 Kura Oncology, Inc. Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
AU2019384646A1 (en) 2018-11-20 2021-06-17 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020106307A1 (fr) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
MA55143A (fr) 2018-11-20 2021-09-29 H Lee Moffitt Cancer Center & Res Institute Inc Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
WO2020132700A1 (fr) 2018-12-21 2020-06-25 Fgh Biotech Inc. Procédés d'utilisation d'inhibiteurs de srebp en combinaison avec du niclosamide et des analogues de celui-ci
EP3897638A1 (fr) 2018-12-21 2021-10-27 Kura Oncology, Inc. Procédé de traitement de carcinomes à cellules squameuses
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2021010603A (es) 2019-03-07 2022-01-31 Conatus Pharmaceuticals Inc Inhibidores de caspasa y metodos de uso de los mismos.
WO2020190604A1 (fr) 2019-03-15 2020-09-24 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
AU2020254492A1 (en) 2019-03-29 2021-11-11 Kura Oncology, Inc. Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3146157A1 (fr) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Composes de sulfone et leurs compositions pharmaceutiques, et leurs applications therapeutiques pour le traitement de maladies neurodegeneratives
CA3146159A1 (fr) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Composes de phenyle et compositions pharmaceutiques associees, et leurs applications therapeutiques
CN114126593B (zh) 2019-07-26 2024-07-26 埃斯佩尔维塔治疗股份有限公司 可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
BR112022004802A2 (pt) 2019-09-16 2022-08-23 Dice Alpha Inc Moduladores de il-17a e usos dos mesmos
EP4034236A1 (fr) 2019-09-26 2022-08-03 Abionyx Pharma SA Composés utiles pour le traitement des maladies du foie
CA3151626A1 (fr) 2019-10-01 2021-04-08 Molecular Skin Therapeutics, Inc. Composes de benzoxazinone utilises comme inhibiteurs doubles de klk5/7
CA3179635A1 (fr) 2020-05-29 2021-12-02 Boulder Bioscience Llc Procedes pour une thrombectomie endovasculaire amelioree a l'aide de 3,3'-diindolylmethane
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
MX2023001741A (es) 2020-08-14 2023-04-25 Siteone Therapeutics Inc Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.
EP4284377A1 (fr) 2021-01-27 2023-12-06 Shy Therapeutics LLC Méthodes pour le traitement d'une maladie fibrotique
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022189856A1 (fr) 2021-03-08 2022-09-15 Abionyx Pharma Sa Composés utiles pour le traitement des maladies du foie
CN117642396A (zh) 2021-03-10 2024-03-01 戴斯分子Sv有限公司 αVβ6和αVβ1整联蛋白抑制剂及其用途
EP4326721A1 (fr) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
WO2022251533A1 (fr) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Hétéroaryl-diamides activateurs d'ire1/xbp1s
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
KR20240110978A (ko) 2021-11-30 2024-07-16 쿠라 온콜로지, 인크. 파네실 전이효소 억제 활성을 갖는 대환식 화합물
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
TW202400593A (zh) 2022-03-28 2024-01-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
US20230348909A1 (en) 2022-03-30 2023-11-02 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
TW202406901A (zh) 2022-04-14 2024-02-16 美商必治妥美雅史谷比公司 新穎gspt1化合物以及新穎化合物之使用方法
WO2023201348A1 (fr) 2022-04-15 2023-10-19 Celgene Corporation Procédés de prédiction de la réactivité d'un lymphome à un médicament et méthodes de traitement du lymphome
WO2023211990A1 (fr) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur
AU2023265665A1 (en) 2022-05-05 2024-10-10 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
WO2024086246A2 (fr) 2022-10-18 2024-04-25 Eluciderm Inc. 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3-djpyrimidin-4-ones substituées en position 2 pour le traitement des plaies
WO2024092040A1 (fr) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Composés hétéroaryle bicycliques contenant un spirocycle
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024118801A1 (fr) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Diamides hétéroaryles linéaires comme activateurs d'ire1/xbp1s
WO2024118810A1 (fr) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Activateurs de ire1/xbp1 diamide de pyrazole cyclique
WO2024145662A1 (fr) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. Compositions de thiazole et de benzothiazole 2-substituées en tant qi'inhibiteurs de dux4 et procédés

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2491537A (en) * 1947-06-03 1949-12-20 Welch Henry Liquid injectable oil-pectin-drug therapeutic compositions
US2807569A (en) * 1953-01-17 1957-09-24 Organon Adrenocorticotropic hormone composition
GB807692A (en) * 1957-05-07 1959-01-21 Lilly Co Eli Corticotropin reaction complexes
US2964448A (en) * 1959-01-27 1960-12-13 Anschel Joachim Relaxin composition and process for preparing same
US3118815A (en) * 1959-09-28 1964-01-21 Upjohn Co Growth hormone and recovery thereof
NL289055A (fr) * 1963-02-15
US3810881A (en) * 1971-06-18 1974-05-14 Ciba Geigy Corp Peptides having d-alpha-phenylglycine,l-lysine and l-ornithine in positions 1,17 and 18,respectively
BE795516A (fr) * 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
GB1454105A (en) * 1972-11-04 1976-10-27 Hoechst Ag Preparation containing luteinizing hormone-releasing factor
US4172138A (en) * 1977-03-23 1979-10-23 Rhodes Russell E Method and composition of matter for the treatment of dry cows for mastitis
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
CA1146866A (fr) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
EP0177342A3 (fr) * 1984-10-04 1987-12-02 Genentech, Inc. Formulations orales de protéines thérapeutiques
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물

Also Published As

Publication number Publication date
AU601272B2 (en) 1990-09-06
PT81248B1 (pt) 1992-10-30
AU4823785A (en) 1986-04-10
EP0177478B2 (fr) 1997-03-05
ZA857642B (en) 1986-08-27
JPH0745409B2 (ja) 1995-05-17
PT81248A1 (pt) 1988-08-01
BG47039A3 (en) 1990-04-16
YU45281B (en) 1992-05-28
KR870003791A (ko) 1987-05-04
GR852398B (fr) 1986-02-03
EP0177478A2 (fr) 1986-04-09
UA8352A1 (uk) 1996-03-29
US5013713A (en) 1991-05-07
PT81248B (pt) 1987-10-20
EP0177478B1 (fr) 1991-04-17
JPS6191130A (ja) 1986-05-09
GEP19960332B (en) 1996-06-24
ES8702440A1 (es) 1986-12-16
ATE132372T1 (de) 1996-01-15
SU1595330A3 (ru) 1990-09-23
KR890002631B1 (ko) 1989-07-21
CN85109638A (zh) 1986-07-30
AU573904B2 (en) 1988-06-23
NO853909L (no) 1986-04-07
PL152711B1 (en) 1991-01-31
CN1044761A (zh) 1990-08-22
DK449585D0 (da) 1985-10-03
NO173975B (no) 1993-11-22
CN1007124B (zh) 1990-03-14
CZ815687A3 (cs) 1998-09-16
YU158485A (en) 1988-12-31
AU1439088A (en) 1988-09-29
DD244914A5 (de) 1987-04-22
NO173975C (no) 1994-03-02
HUT38839A (en) 1986-07-28
DK449585A (da) 1986-04-05
DE3588074D1 (de) 1996-02-15
CZ284472B6 (cs) 1998-12-16
CS274717B2 (en) 1991-10-15
ES547489A0 (es) 1986-12-16
IE852422L (en) 1986-04-04
HU196714B (en) 1989-01-30
CN1031038C (zh) 1996-02-21
NZ213701A (en) 1988-08-30
IE65392B1 (en) 1995-10-18
US5739108A (en) 1998-04-14
PL261273A1 (en) 1987-08-10
DE3582548D1 (de) 1991-05-23
EP0177478A3 (en) 1987-04-01
PL255622A1 (en) 1986-12-30
IL76554A0 (en) 1986-02-28
CS711885A2 (en) 1987-11-12
PT81248A (en) 1985-11-01
CA1309018C (fr) 1992-10-20

Similar Documents

Publication Publication Date Title
IL76554A (en) Prolonged release of biologically active somatotropins
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
IT1219072B (it) Procedimento per la peparazione di ossidi superconduttivi e compositi ossidometallo
GR3009561T3 (fr)
CA2000722A1 (fr) Materiau supraconducteur composite a matrice metallique et procede de fabrication
POTAPOV Condition of rats connective tissue during long-term hypokinesia and in recovery period
TCHEICHVILI MANKIND'S DEBT TO CLAY
RO103469A2 (en) Paste composition for hardening
SU1178276A1 (ru) Электролит для химического источника тока
Glezer et al. Structural features of a Sendust alloy(Fe-Si-Al) obtained by quenching from the melt. II. Quenching defects.
Aghajanian et al. Metal Matrix Composites and Techniques for Making the Same
Nosovskii et al. Study by Acoustic Emission of the Deformation and Fracture of Surface Layers of Metals During Friction
Junkers Experiences With Spring Elements for the Stabilisation of Precipitation Electrodes in Electrofilters
Danev Development of Economic Studies in Ferrous Metallurgy
Rahn Chemical clues to the origin of acid rain in New England.
DE3469682D1 (en) Catalyst composition
HUT37338A (en) Method for producing meat fluor securing the optimum function of alimentary canal
EP0309120A3 (fr) Peptide atrial à action hypotensive
SE8200142L (sv) Pelarkran
SU1241637A1 (ru) Способ активации водородосорбционного сплава

Legal Events

Date Code Title Description
RH1 Patent not in force